-TumorSight™ is a cloud-based digital precision medicine platform intended to support the end-to-end patient journey -TumorSight™ Viz, the first FDA cleared TumorSight™ application, provides clinicians with key 3D spatial visualizations of the tumor and surrounding tissue to bring imaging to…

January 02, 2024 07:00 AM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine precision medicine for cancer, announced today it has entered into a strategic…

December 18, 2023 07:00 AM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine precision medicine for cancer, announced today it has entered a strategic collaboration…

CHICAGO – JUNE 3, 2022 — SimBioSys, the technology company that predicts tumor responses to therapy, announced today it will showcase research at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022 taking place in Chicago from June 3-7.…

The company’s first appearance at this prestigious cancer research conference profiles use cases of platform for cancer treatment planning and as a cancer research tool.

Genoa Ventures and Northpond Ventures co-lead investment in precision medicine platform that develops virtual tumors in 3D to predict response to therapy using standard-of-care data